CN1246038C - 全身性送递肉毒杆菌毒素口服疫苗 - Google Patents

全身性送递肉毒杆菌毒素口服疫苗 Download PDF

Info

Publication number
CN1246038C
CN1246038C CNB988112981A CN98811298A CN1246038C CN 1246038 C CN1246038 C CN 1246038C CN B988112981 A CNB988112981 A CN B988112981A CN 98811298 A CN98811298 A CN 98811298A CN 1246038 C CN1246038 C CN 1246038C
Authority
CN
China
Prior art keywords
asn
ile
ser
leu
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988112981A
Other languages
English (en)
Chinese (zh)
Other versions
CN1290174A (zh
Inventor
L·辛普森
N·基亚特肯
A·马克思莫威克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of CN1290174A publication Critical patent/CN1290174A/zh
Application granted granted Critical
Publication of CN1246038C publication Critical patent/CN1246038C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/832—Drug, bio-affecting and body treating compositions involving bacterial toxin that has modified amino acid sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CNB988112981A 1997-10-20 1998-10-16 全身性送递肉毒杆菌毒素口服疫苗 Expired - Fee Related CN1246038C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/954,302 US6051239A (en) 1997-10-20 1997-10-20 Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
US08/954,302 1997-10-20

Publications (2)

Publication Number Publication Date
CN1290174A CN1290174A (zh) 2001-04-04
CN1246038C true CN1246038C (zh) 2006-03-22

Family

ID=25495232

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB988112981A Expired - Fee Related CN1246038C (zh) 1997-10-20 1998-10-16 全身性送递肉毒杆菌毒素口服疫苗

Country Status (16)

Country Link
US (1) US6051239A (enExample)
EP (1) EP1024827B1 (enExample)
JP (1) JP2001522783A (enExample)
KR (1) KR100594787B1 (enExample)
CN (1) CN1246038C (enExample)
AT (1) ATE355076T1 (enExample)
AU (1) AU756475B2 (enExample)
BR (1) BR9815255A (enExample)
CA (1) CA2306995A1 (enExample)
DE (1) DE69837209T2 (enExample)
EE (1) EE200000536A (enExample)
HU (1) HUP0101017A3 (enExample)
IL (1) IL135743A (enExample)
NZ (1) NZ504549A (enExample)
RU (1) RU2227042C2 (enExample)
WO (1) WO1999020306A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7227010B2 (en) 1993-09-21 2007-06-05 United States Of America As Represented By The Secretary Of The Army Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US6967088B1 (en) * 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
EP1514556B1 (en) * 2000-02-08 2011-08-10 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
WO2002036758A2 (en) * 2000-11-06 2002-05-10 United States Army Medical Research And Material Command Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
JP4707254B2 (ja) * 2001-04-24 2011-06-22 クミアイ化学工業株式会社 粒状組成物及びその製造方法
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US7491403B2 (en) * 2002-12-20 2009-02-17 Botulinum Toxin Research Associates Pharmaceutical botulinum toxin compositions
US20040013687A1 (en) * 2002-05-31 2004-01-22 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US20040086532A1 (en) * 2002-11-05 2004-05-06 Allergan, Inc., Botulinum toxin formulations for oral administration
AU2003287622A1 (en) 2002-11-06 2004-06-03 Fraunhofer Usa Expression of foreign sequences in plants using trans-activation system
US8148608B2 (en) * 2004-02-20 2012-04-03 Fraunhofer Usa, Inc Systems and methods for clonal expression in plants
US7692063B2 (en) * 2002-11-12 2010-04-06 Ibio, Inc. Production of foreign nucleic acids and polypeptides in sprout systems
US7683238B2 (en) * 2002-11-12 2010-03-23 iBio, Inc. and Fraunhofer USA, Inc. Production of pharmaceutically active proteins in sprouted seedlings
EP1594956A4 (en) * 2003-02-03 2007-08-01 Fraunhofer Usa Inc SYSTEM FOR EXPRESSION OF GENES IN PLANTS
US20040253274A1 (en) * 2003-06-11 2004-12-16 Allergan, Inc. Use of a clostridial toxin to reduce appetite
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
US20050129677A1 (en) * 2003-12-10 2005-06-16 Shengwen Li Lipid rafts and clostridial toxins
US7306807B2 (en) * 2004-09-13 2007-12-11 Wyeth Hemorrhagic feline calicivirus, calicivirus vaccine and method for preventing calicivirus infection or disease
CA2588758C (en) * 2004-11-22 2017-01-03 New York University Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
EP2471550A1 (en) 2005-10-07 2012-07-04 Health Protection Agency Proteins with improved solubility and methods for producing and using same
PH12011502633A1 (en) 2005-10-07 2012-11-12 Zoetis P Llc Vaccines and methods to treat canine influenza
MX2009013030A (es) * 2007-05-30 2010-03-25 Wyeth Llc Poxvirus de mapache que expresa genes de antigenos felinos.
WO2009042165A2 (en) * 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
CA2745657C (en) 2008-12-04 2022-06-21 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
JP2016513082A (ja) 2013-01-28 2016-05-12 ニューヨーク・ユニバーシティ 無毒性神経毒誘導体を用いる治療方法
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
EP3230457B1 (en) 2014-12-09 2021-06-30 New York University Clostridial neurotoxin fusion proteins, propeptide fusions, their expression, and use
US11149262B2 (en) 2017-12-20 2021-10-19 Alleergan, Inc. Botulinum toxin cell binding domain polypeptides and methods of use for skin rejuvenation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919665A (en) * 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US6203794B1 (en) * 1994-05-31 2001-03-20 Allergan Sales, Inc. Modification of clostridial toxins for use as transport proteins
CZ296806B6 (cs) * 1994-10-24 2006-06-14 Allergan, Inc. Rozpustný fúzní protein a zpusob výroby rozpustného rekombinantního botulinového toxinu
WO1996040229A1 (en) * 1995-06-07 1996-12-19 Thomas Jefferson University Vaccines synthesized by transgenic plants
WO1997032599A1 (en) * 1996-03-08 1997-09-12 The Regents Of The University Of California Chemically-modified clostridiatoxin with improved properties

Also Published As

Publication number Publication date
EP1024827A1 (en) 2000-08-09
WO1999020306A1 (en) 1999-04-29
DE69837209D1 (de) 2007-04-12
US6051239A (en) 2000-04-18
DE69837209T2 (de) 2007-10-31
HUP0101017A3 (en) 2003-11-28
CA2306995A1 (en) 1999-04-29
RU2227042C2 (ru) 2004-04-20
KR20010031236A (ko) 2001-04-16
KR100594787B1 (ko) 2006-07-03
AU1094799A (en) 1999-05-10
IL135743A (en) 2004-03-28
HUP0101017A2 (hu) 2001-07-30
AU756475B2 (en) 2003-01-16
BR9815255A (pt) 2001-12-26
EP1024827A4 (en) 2002-08-28
ATE355076T1 (de) 2006-03-15
EE200000536A (et) 2002-04-15
EP1024827B1 (en) 2007-02-28
CN1290174A (zh) 2001-04-04
NZ504549A (en) 2002-12-20
IL135743A0 (en) 2001-05-20
JP2001522783A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
CN1246038C (zh) 全身性送递肉毒杆菌毒素口服疫苗
CN1191362C (zh) 新颖的链球菌抗原
CN1155707C (zh) 鼠疫疫苗
CN1297316C (zh) 作为佐剂的霍乱全毒素的突变体形式
CN1214114C (zh) 可活化的重组神经毒素
CN1145697C (zh) 治疗和诊断组合物
CN1541111A (zh) 作为佐剂的霍乱全毒素的突变形式
CN1284884A (zh) 疫苗
CN1320043A (zh) 突变霍乱全毒素佐剂
CN1171814A (zh) 多核苷酸结核病疫苗
CN1419564A (zh) 包含脑膜炎奈瑟氏球菌表面抗原NhhA的保守区域的蛋白质
CN1318105A (zh) 负调节Osteoprotegerin配体活性的方法
CN1659187A (zh) 融合铁蛋白在疫苗和其他方面的应用
CN1918176A (zh) 用于诱导针对金黄色葡萄球菌的保护性免疫反应的多肽
CN1426471A (zh) 奈瑟球菌蛋白质的杂交表达
CN1909924A (zh) 含有细菌鞭毛蛋白作为活性成分的粘膜疫苗佐剂
CN1798762A (zh) 效能提高的结核病疫苗
CN101054582A (zh) A型肉毒毒素受体结合区Hc基因及其编码蛋白与应用
CN1212016A (zh) 重组的核糖核酸酶蛋白质
CN1215167C (zh) 幽门螺杆菌活疫苗
CN1211487C (zh) 链球菌毒素a突变体及其使用方法
CN1956727A (zh) 诱导抗金黄色葡萄球菌的保护性免疫应答的多肽
CN1198918C (zh) 减毒的活胸膜肺炎放线杆菌
CN1741818A (zh) 线虫多肽佐剂
CN101031647A (zh) 在大肠杆菌中制备猪丹毒杆菌表面保护性抗原变体的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee